We assessed the impact of each splice variant on CLL prognostic markers, including the IGHV, TP53, NOTCH1, SF3B1, and MYD88 mutational status, cytogenetic aberrations, and laboratory features. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.